CSII is related to more stable glycemia in adults with type 1 diabetes

Abstract

The purpose of the present study was to compare the basic glycemic control parameters—HbA1c, CV%, and hypoglycemia, as well as quality of life and depression score in patients with type 1 diabetes using continuous subcutaneous insulin infusion (CSII) versus multiple daily injections (MDI). 324 adult patients with type 1 diabetes—146 using CSII and 178 on MDI, were enrolled in this cross-sectional study. HbA1c was assessed in whole blood by immuno-turbidimetric NGSP certified method. CV% was derived from CGM or was calculated from a 9-point capillary blood glucose profile. Hypoglycemia frequency, severity, and awareness were assessed using Clarke’s hypoglycemia questionnaire. Quality of life (QOL) was assessed using a questionnaire by the Psychiatric Research Unit and the CES-D scale. CSII group compared to MDI group showed significantly lower HbA1c—7.3% (6.6–8.0%) vs 8.2% (7.2–9.6%) (p\u2009<\u20090.0001), lower CV 27.2% (±9.8) vs 34.7% (±11.3) (p\u2009<\u20090.0001), fewer hypoglycemia episodes (p\u2009<\u20090.0001). There was no significant difference in the frequency of severe hypoglycemia, hypoglycemia awareness, QOL, and depression scores between the two groups. CSII in type 1 diabetes is related to better and more stable glycemic control compared to MDI.